|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Psoriasis
This is a fluctuating but persistent skin disease that gets its name from the Greek word for "itch." The skin is inflamed, with red, thickened areas bearing silvery scales; it's seen most often on the elbows, knees, scalp, and lower back. It may be so mild that people don't know they have it. At the other end of the spectrum, severe psoriasis may cover large areas of the body.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Psoriasis Study -A2303
This study will assess the safety and efficacy of an "investigational drug" compared to placebo and existing drug in patients that have moderate to severe, chronic, plaque-type psoriasis. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). This investigational drug may not become commercially available.
Trial phase: Phase 3 Participation Duration: 1 year Protocol Number: CAIN457A2303 Psoriasis Study - A2304
This study will assess the safety and efficacy of two different doses and two different dose regimens of an "investigational drug" in patients that have moderate to severe, chronic, plaque-type psoriasis. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). This investigational drug may not become commercially available.
Trial phase: Phase 3 Participation Duration: 1 year Protocol Number: CAIN457A2304 |